Boardroom Alpha
Boardroom Alpha
MEDP · Current Report (Form 8-K) · Filed May 19, 2026

Medpace Holdings Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 19, 2026
Period
May 15, 2026
Ticker
MEDP
Accession
0001193125-26-230425
Boardroom Alpha · Filing insights

Stockholders approve amendments removing supermajority voting and the right to call special meetings; effective May 18, 2026.

About Medpace Holdings Inc
Market cap
$12.7B
1Y TSR
+40.8%
3Y TSR
+24.7%
Board grade
A-
Sector
Healthcare
CEO
August J Troendle
Last annual meeting: May 15, 2026 · View full Medpace Holdings Inc profile →
8-K
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 15, 2026

 

 

MEDPACE HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-37856   32-0434904

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

5375 Medpace Way

Cincinnati, Ohio 45227

(Address of Principal Executive Offices, and Zip Code)

(513) 579-9911

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock $0.01 par value   MEDP   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.03.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At the Medpace Holdings, Inc. (the “Company”) 2026 Annual Meeting of Stockholders held on May 15, 2026 (the “2026 Annual Meeting”), stockholders approved separate amendments (the “Amendments”) to the Restated Certificate of Incorporation of the Company, each as described in the Company’s proxy materials related to the 2026 Annual Meeting, (i) to remove supermajority voting requirements and (ii) to remove the limitation on stockholders calling special meetings of stockholders. The Amendments became effective immediately upon the filing of a certificate of amendment setting forth the same with the Secretary of State of the State of Delaware on May 18, 2026. Following the filing of this certificate of amendment, the Company filed a Restated Certificate of Incorporation of the Company integrating the same with the Secretary of State of the State of Delaware on May 18, 2026, which became effective upon filing.

In connection with the Amendments, the Board approved amendments to the Second Amended and Restated Bylaws of the Company to remove the limitation on stockholders calling special meetings of stockholders, to provide one or more stockholders as a group owning at least 25% of the voting power of the Company’s outstanding shares the right to call a special meeting, and to implement other conforming and clarifying changes (the “Bylaw Amendments”). The right of stockholders to request that the Company call special meetings is also subject to notice, information, and other requirements and limitations set forth in the Third Amended and Restated Bylaws of the Company, including a requirement that the requesting stockholders must have continuously owned at least 25% of the voting power of our outstanding shares for one year.

The foregoing summaries of the Amendments and the Bylaw Amendments are qualified in their entirety by reference to the full text of the Restated Certificate of Incorporation and the Third Amended and Restated Bylaws, as set forth in Exhibits 3.1 and 3.2 to this Current Report on Form 8-K, respectively, and incorporated herein by reference.

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

 

  (a)

On May 15, 2026, the Company held its 2026 Annual Meeting.

 

  (b)

Stockholders voted on the matters set forth below.

Proposal 1 — Election of Directors

The following nominees were elected to the Company’s Board of Directors to serve as Directors until the Company’s 2027 Annual Meeting of Stockholders based upon the following votes:

 

     Votes
For
     Votes
Withheld
     Broker
Non-Votes
 

Brian T. Carley (Class I)

     22,251,529        2,170,699        1,545,538  

Femida H. Gwadry-Sridhar (Class I)

     23,736,619        685,609        1,545,538  

Robert O. Kraft (Class I)

     22,148,880        2,273,348        1,545,538  

August J. Troendle (Class III)

     23,900,589        521,639        1,545,538  

Dani S. Zander (Class III)

     23,721,072        701,156        1,545,538  

 


Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm

The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based upon the following votes:

 

Votes
For

  

Votes
Against

  

Votes
Abstained

  

Broker
Non-Votes

25,269,569    675,125    23,072    — 

Proposal 3 — Advisory Vote on the Compensation of Our Named Executive Officers

The proposal to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers was approved based upon the following votes:

 

Votes
For

 

Votes
Against

 

Votes
Abstained

 

Broker
Non-Votes

22,656,335   1,737,558   28,335   1,545,538

Proposal 4 — Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of Our Named Executive Officers

The proposal to approve, on an advisory basis, the frequency of future advisory votes on the compensation of the Company’s Named Executive Officers received the following votes:

 

Votes For

One Year

 

Votes For

Two Years

 

Votes For

Three Years

 

Votes Abstained

23,989,262   12,741   402,376   17,849

Proposal 5 — Amendment to the Company’s Certificate of Incorporation to Remove Supermajority Voting Requirements.

The proposal to amend the Company’s Certificate of Incorporation to remove supermajority voting requirements was approved based upon the following votes:

 

Votes

For

 

Votes

Against

 

Votes

Abstained

 

Broker

Non-Votes

24,311,938   95,085   15,205   1,545,538

Proposal 6 — Amendment to the Company’s Certificate of Incorporation to Remove the Limitation on Stockholders Calling Special Meetings of Stockholders.

The proposal to amend the Company’s Certificate of Incorporation to remove the limitation on stockholders calling special meetings of stockholders was approved based upon the following votes:

 

Votes

For

 

Votes

Against

 

Votes

Abstained

 

Broker

Non-Votes

22,596,141   322,485   1,503,602   1,545,538

 


Proposal 7 — Advisory Vote on Stockholder Proposal

The non-binding advisory stockholder proposal regarding giving shareholders an ability to call for a special shareholder meeting received the following votes:

 

Votes

For

 

Votes

Against

 

Votes

Abstained

 

Broker

Non-Votes

8,306,071

  16,081,493   34,664   1,545,538

(c) Not applicable.

(d) Based upon the results set forth in item (b) (Proposal 4) above, and consistent with the Board’s recommendation, the Board of Directors has determined that advisory votes on executive compensation will be submitted to stockholders on an annual basis until the next required vote on the frequency of such votes.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

No.

  

Description

3.1    Restated Certificate of Incorporation
3.2    Third Amended and Restated Bylaws
104    Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MEDPACE HOLDINGS, INC.
Date: May 19, 2026     By:  

/s/ Stephen P. Ewald

    Name:   Stephen P. Ewald
    Title:   General Counsel and Corporate Secretary
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Medpace Holdings Inc (MEDP)

Reference

Frequently asked questions

When did Medpace Holdings Inc file this 8-K?
Medpace Holdings Inc (MEDP) filed this Current Report (Form 8-K) with the SEC on May 19, 2026. The accession number assigned by EDGAR is 0001193125-26-230425.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders approve amendments removing supermajority voting and the right to call special meetings; effective May 18, 2026. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Medpace Holdings Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Medpace Holdings Inc has filed under CIK 1668397, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer